N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.
Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.
The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.
The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.
A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
An 18-year-old male is experiencing significant hair shedding, particularly from the back of his head, despite normal blood test results except for slightly low vitamin D. A dermatologist prescribed minoxidil for receding temples, but the cause of the shedding remains unclear.
The conversation discusses various factors affecting hair loss, not just DHT, and mentions treatments like Minoxidil, finasteride, and melatonin. Some users report personal experiences with these treatments and hormone tests, while others speculate on the role of hormones like prolactin and cortisol in hair loss.
Female (37) experiencing hair loss for 5 years, tried max dose of spiro and oral + topical minox without success. Discovered low cortisol and low DHEA levels, seeking functional medicine practitioner for help.
A 22-year-old male experiencing hair thinning is considering starting finasteride but is concerned about potential side effects and hereditary factors. While waiting to access finasteride, he plans to use pumpkin seed oil, saw palmetto, biotin, and vitamins, and is advised to check blood levels before starting treatment.
Stopping finasteride often leads to rapid hair loss, returning to a genetic baseline, as the drug temporarily halts hair loss and promotes regrowth. The discussion explores the complexity of hair loss, suggesting that factors beyond DHT, such as genetics and scalp conditions, may play a role.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
Stress can trigger hair loss, with treatments like minoxidil, finasteride, and dutasteride being used to manage it. Some users report improvement with medications like Lexapro, while others emphasize the impact of stress and life events on hair health.
The user underwent a biopsy two years ago and was diagnosed with keratosis pilaris, leading to hair issues. They tried treatments including Minoxidil, betamethasone, lymecycline, topical Accutane, and dutasteride, as well as diet changes, without improvement in hair thickness or skin dryness.
A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
The conversation is about whether treatments like finasteride, dutasteride, and minoxidil can make single hair follicles produce multiple hairs again. The user is curious if these medications can thicken hair and prolong the growth phase.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.
A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.